It can be annoying if your bladder seems to work overtime and you're headed to the bathroom more often than you'd like, but that doesn't necessarily mean you need medication or that you even have a ...

A new study suggests that more women are being prescribed beta-3 agonists over anticholinergics for the treatment of overactive bladder (OAB), suggesting that more clinicians may be choosing this ...

The FDA has approved mirabegron for the treatment of overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency, and urinary frequency. The drug, marketed by Astellas Pharma Inc.

Overactive bladder is a long-term condition that won’t go away on its own and may worsen if a person does not get treatment. The condition can be caused by issues in how the brain and bladder ...

Credit: Getty Images. Results are from a meta-analysis of 33 trials involving 35,939 patients with overactive bladder. Overactive bladder treatment using antimuscarinic drugs increases the risks for ...

(Reuters) - Watson Pharmaceuticals Inc said it signed a deal to market Antares Pharma Inc's experimental treatment for overactive bladder in the United States and Canada. According to the terms of the ...

Bladder leaks can be disruptive—and they’re very common. Up to 30 percent of older adults experience incontinence. The problem is more prevalent in women, but the percentage of men with an overactive ...

Active ingredient: Fesoterodine fumarate 4 mg, 8 mg; extended-release tablets. Indication: Overactive bladder (OAB) with urge urinary incontinence, urgency, and frequency. Pharmacology: Fesoterodine ...

Watch Virginia This Morning each weekday from 9 to 10 a.m. Find the show on Facebook and Instagram at @VirginiaThisMorning.

DelveInsight's "Overactive Bladder Market Insights, Epidemiology, and Market Forecast 2032" report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as ...

NEW YORK, June 6 (Reuters) - One of the most common problems in the United States -- an overactive bladder -- is so poorly treated by the current crop of drugs that new medicines have big sales ...

After successful Phase 3 trials, Indevus Pharmaceuticals Inc. has received a $10 million milestone payment from its partner in the development of overactive-bladder drugs Sanctura and Sactura XR, ...